Status:

UNKNOWN

Biomarkers Guided Stopping NAs Treatment

Lead Sponsor:

Nanfang Hospital, Southern Medical University

Conditions:

Chronic Hepatitis b

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

The primary objective of this study is to evaluate hepatitis B surface antigen (HBsAg) loss in subjects who stop nucles(t)ide analogues (NAs) (Stop arm) compared to subjects who continue (Continue arm...

Eligibility Criteria

Inclusion

  • Key
  • 18-65 years of old, male or female
  • Chronic hepatitis B patients
  • Received continuous ETV, TDF or TAF therapy for at least 1 year prior to screening and at screening
  • For patients with Hepatitis B e Antigen (HBeAg)-positive at the beginning of NAs therapy, documented hepatitis B virus \<20 IU/mL, HBeAg seroconversion and ALT normalization for at least 1 year prior to screening and at screening
  • For patients with HBeAg-negative at the beginning of NAs therapy, documented hepatitis B virus \<20 IU/mL, and ALT normalization for at least 3 year prior to screening and at screening
  • \<= 9 kPa on Fibroscan assessment
  • qHBsAg \<200 IU/mL within 24 weeks prior to screening
  • HBV RNA or HBcrAg negativity within 24 weeks prior to screening
  • Key

Exclusion

  • Experience of IFN treatment within 1 year prior to screening
  • Known cirrhosis
  • History of decompensated liver disease
  • History of clinical hepatic decompensation in the judgement of the investigator
  • Evidence of hepatocellular carcinoma
  • Serological evidence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus, or hepatitis D infection
  • Known hypersensitivity to TDF, its metabolites, or formulation excipients
  • History of malignant disease
  • Lactating females
  • Females wishing to became pregnant during the duration of the study
  • Subjects participating in another clinical trial

Key Trial Info

Start Date :

July 6 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2023

Estimated Enrollment :

195 Patients enrolled

Trial Details

Trial ID

NCT04519359

Start Date

July 6 2020

End Date

June 30 2023

Last Update

August 19 2020

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

2

Peking University People's Hospital

Beijing, Beijing Municipality, China

3

No. 1 Hospital affiliated to Jilin University

Changchun, Jilin, China

4

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China